Lonza (Basel, Switzerland) announce the launch of four new services to expand their early phase biopharmaceutical drug development.
2. Given the complexity and cost of development and manufacturing, are biosimilars more affordable therapeutic options?
In this ‘Ask the Experts’ feature, the experts discuss the complexity and cost of development and whether biosimilars are more affordable therapeutic options.
12. How do you see the field evolving over the next 5-10 years? What are the main obstacles to be overcome?
In our final instalement, our experts look towards the future and comment on how they see the field evolving over the next 5-10 years.
Available to view on demand: In this webinar, Glenn Petrie discusses best practice in optimizing the Chemistry, Manufacturing and Control (CMC) process.
Available to view on demand
In this presentation, the results of an exploration of HRMS for the quantitative determination of biopharmaceutical proteins and a comparison to nominal mass LC-MS/MS will be provided, including validation results and application to preclinical trials.
Meeting Report: 30th International Symposium, Exhibit and Workshops on Preparative and Process Chromatography
The 30th International Symposium, Exhibit was held in Philadelphia, PA, on July 16-19, 2017 at the Loews Hotel.The symposium was attended by more than 320 people from 21 different countries
Available to view on demand: In this webinar, Glenn Petrie discusses the key to rapid investigational new drug submission and approval in ADC developlment.
This infographic presents key results from the bioanalysis of biopharmaceuticals and biomarkers survey.
In this commentary, the authors discuss the benefits and challenges of using ‘ready-to-use’ cells from a frozen bank of uniform, tested, aliquots.
The CRO BioPharmaSpec, have announced plans to increase in-house capabilities, including the 3D structure characterization of proteins.